Molecular structure of (S)-(−)-Warfarin, CAS Number: 5543-57-7
(S)-(−)-Warfarin (CAS 5543-57-7)
Application:
(S)-(−)-Warfarin is a CYP2C9 substrate
CAS Number:
5543-57-7
Molecular Weight:
308.33
Molecular Formula:
C19H16O4
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
CYP2C9 substrate; anticoagulant.
(S)-(−)-Warfarin (CAS 5543-57-7) References
- Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes. | Hemeryck, A., et al. 1999. Eur J Clin Pharmacol. 54: 947-51. PMID: 10192756
- CYP2C9-catalyzed metabolism of S-warfarin to 7-hydroxywarfarin in vivo and in vitro in chimeric mice with humanized liver. | Inoue, T., et al. 2008. Drug Metab Dispos. 36: 2429-33. PMID: 18784266
- Effect of ethanol on S-warfarin and diclofenac metabolism by recombinant human CYP2C9.1. | Tatsumi, A., et al. 2009. Biol Pharm Bull. 32: 517-9. PMID: 19252308
- New high-performance liquid chromatography method for the determination of (R)-warfarin and (S)-warfarin using chiral separation on a glycopeptide-based stationary phase. | Malakova, J., et al. 2009. J Chromatogr B Analyt Technol Biomed Life Sci. 877: 3226-30. PMID: 19643683
- Simultaneous measurement of S-warfarin, R-warfarin, S-7-hydroxywarfarin and R-7-hydroxywarfarin in human plasma by liquid chromatography-tandem mass spectrometry. | Zuo, Z., et al. 2010. J Pharm Biomed Anal. 52: 305-10. PMID: 20133101
- Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin. | Jones, DR., et al. 2010. Drug Metab Lett. 4: 213-9. PMID: 20615193
- Quantification of total and free concentrations of R- and S-warfarin in human plasma by ultrafiltration and LC-MS/MS. | Jensen, BP., et al. 2011. Anal Bioanal Chem. 401: 2187-93. PMID: 21830136
- Impact of organic solvents on cytochrome P450 probe reactions: filling the gap with (S)-Warfarin and midazolam hydroxylation. | González-Pérez, V., et al. 2012. Drug Metab Dispos. 40: 2136-42. PMID: 22896727
- Monkey liver cytochrome P450 2C19 is involved in R- and S-warfarin 7-hydroxylation. | Hosoi, Y., et al. 2012. Biochem Pharmacol. 84: 1691-5. PMID: 23041648
- 1-Aminobenzotriazole coincubated with (S)-warfarin results in potent inactivation of CYP2C9. | Sodhi, JK., et al. 2014. Drug Metab Dispos. 42: 813-7. PMID: 24550229
- Novel Marmoset Cytochrome P450 2C19 in Livers Efficiently Metabolizes Human P450 2C9 and 2C19 Substrates, S-Warfarin, Tolbutamide, Flurbiprofen, and Omeprazole. | Uehara, S., et al. 2015. Drug Metab Dispos. 43: 1408-16. PMID: 26228688
- Comparative pharmacokinetics of coumarin anticoagulants. XLIX: Nonlinear tissue distribution of S-warfarin in rats. | Cheung, WK. and Levy, G. 1989. J Pharm Sci. 78: 541-6. PMID: 2778653
- The effect of S-warfarin administration on vitamin K 2,3-epoxide reductase activity in liver, kidney and testis of the rat. | Thijssen, HH., et al. 1986. Biochem Pharmacol. 35: 3277-82. PMID: 3768021
- Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. | Yamazaki, H. and Shimada, T. 1997. Biochem Pharmacol. 54: 1195-203. PMID: 9416970
Substrate of:
CYP2C9.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
(S)-(−)-Warfarin, 1 mg | sc-253488B | 1 mg | $168.00 | |||
(S)-(−)-Warfarin, 5 mg | sc-253488 | 5 mg | $515.00 | |||
(S)-(−)-Warfarin, 10 mg | sc-253488A | 10 mg | $740.00 | |||
(S)-(−)-Warfarin, 25 mg | sc-253488C | 25 mg | $1637.00 | |||
(S)-(−)-Warfarin, 50 mg | sc-253488D | 50 mg | $2861.00 |